Financial Statement Analysis
FINANCIAL STATEMENT ANALYSIS PROJECT
Presented By
Group Leader:
Table of contents: -
1. SECTION 1: EXECUTIVE SUMMARY ………………………….…. 2
2. SECTION 2: BALANCE SHEET ANALYSIS ……………………………….. 4
3. SECTION 3: INCOME STATEMENT…………………………………………17
4. SECTION 4: RATIO ANALYSIS………………………………………………27
5. SECTION 5: CONCLUSIONS/RECOMMENDATIONS……………….…......30
6. SECTION 6: PUBLIC PERCEPTION AND RECENT RESULTS………….…31 7. APPENDIX 38
Date:-03/08/14
SECTION 1: EXECUTIVE SUMMARY
ABBOTT LABORATORIES: -
• Official name of the corporation : - Abbott Laboratories (ABT)
• Location of the corporate headquarters: - 100 Abbott Park Road
• Abbott Park, Illinois 60064-6400, US
• The state in which the company is incorporated: - Illinois, U.S.
• Company Internet address: - http://www.abbott.com
• Stock symbol of the corporation and the exchange on which it is traded: - ABT
• Fiscal year-end of the corporation: - January 1st to December 31st
• Date of the 10-K filing according to the financial statements provided: - February 21st 2014
• The company’s independent accountant/auditor: - Principle Accountant: Mr. Robert E. Funck, Auditor: Deloitte & Touche LLP (Deloitte)
• The primary products(s) and/or services (s) of the corporation:-
• Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
Details of each segment are as follow:
Established Pharmaceutical Products:
These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States, and are generally sold directly to wholesalers, distributors, government agencies,
Presented By
Group Leader:
Table of contents: -
1. SECTION 1: EXECUTIVE SUMMARY ………………………….…. 2
2. SECTION 2: BALANCE SHEET ANALYSIS ……………………………….. 4
3. SECTION 3: INCOME STATEMENT…………………………………………17
4. SECTION 4: RATIO ANALYSIS………………………………………………27
5. SECTION 5: CONCLUSIONS/RECOMMENDATIONS……………….…......30
6. SECTION 6: PUBLIC PERCEPTION AND RECENT RESULTS………….…31 7. APPENDIX 38
Date:-03/08/14
SECTION 1: EXECUTIVE SUMMARY
ABBOTT LABORATORIES: -
• Official name of the corporation : - Abbott Laboratories (ABT)
• Location of the corporate headquarters: - 100 Abbott Park Road
• Abbott Park, Illinois 60064-6400, US
• The state in which the company is incorporated: - Illinois, U.S.
• Company Internet address: - http://www.abbott.com
• Stock symbol of the corporation and the exchange on which it is traded: - ABT
• Fiscal year-end of the corporation: - January 1st to December 31st
• Date of the 10-K filing according to the financial statements provided: - February 21st 2014
• The company’s independent accountant/auditor: - Principle Accountant: Mr. Robert E. Funck, Auditor: Deloitte & Touche LLP (Deloitte)
• The primary products(s) and/or services (s) of the corporation:-
• Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
Details of each segment are as follow:
Established Pharmaceutical Products:
These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States, and are generally sold directly to wholesalers, distributors, government agencies,